Livanova Plc · NASDAQ:LIVN
Livanova — Investor Day (September 2017)
19 slides from Livanova's investor day presentation, Sep 14, 2017
Slide 1: LivaNova Investor Day
NEUROMODULATION LivaNova Investor Day Heart Valves Strategy Damien McDonald Chief Executive Officer September 14, 2017 CARDIAC SURGERY
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements in this presentation, other than purely historical information, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 19
Slide 3: We are a $1.2B focused medical innovator
We are a $1.2B focused medical innovator Strong leadership Targeting underserved Improving quality of position in and high-growth patients’ lives Neuromodulation and market segments Cardiac Surgery 3
Slide 4: Leading positions in critical areas of treatment
Leading positions in critical areas of treatment 80% Sales 1H17 Vagus Nerve Stimulation Cardiopulmonary (CP) (VNS Therapy®) Heart-lung machines (HLM) Oxygenators Neuro- Autotransfusion systems (ATS) modulation Cannulae (NM) Cardiac 60% Surgery Low voltage 30% (CS) 50% Pacemakers Cardiac CRT-P Rhythm
Slide 5: Exploring strategic options for Cardiac Rhythm Management
Exploring strategic options for Cardiac Rhythm Management Sharpening our focus on areas of strength and market leadership Committed to ensuring portfolio is optimally positioned to deliver long-term value CRM is no longer a fit within LivaNova’s portfolio, but is a global business with attractive as
Slide 6: Committed to ensuring portfolio is optimally positioned to deliver long-term value
Committed to ensuring portfolio is optimally positioned to deliver long-term value Leading positions in Neuromodulation and Cardiac Surgery Innovative technology focusing on high-margin products LivaNova: An attractive Targeting high-growth and underserved markets long-term investment Executing disc
Slide 7: Focusing portfolio on "Head & Heart"
Focusing portfolio on “Head & Heart” CARDIAC SURGERY NEUROMODULATION CARDIOPULMONARY HEART VALVES Creator, leader of VNS Only sutureless valve on Market-leading positions Therapy the market Global Market $4.1B $2.0B $1.7B (2016)* Market Growth Low-double-digit Low-single-digit Low-single-digit Sales
Slide 8: Our portfolio has multiple near-term growth drivers
Our portfolio has multiple near-term growth drivers NEUROMODULATION CARDIAC SURGERY Perceval® optimizes the S5® HLM reduces Inspire® oxygenator surgical approach to AspireSR® advances the transfusions and provides personalized sutureless aortic science of VNS Therapy® improves recovery perfusion val
Slide 9: Our portfolio has multiple mid- to long-term growth drivers
Our portfolio has multiple mid- to long-term growth drivers: strategic portfolio initiatives TREATMENT-RESISTANT TRANSCATHETER MITRAL CHRONIC HEART FAILURE DEPRESSION VALVE REPLACEMENT Novel delivery of Autonomic VNS Therapy may provide Unique transseptal Regulation Therapy (ART) may better outcomes
Slide 10: M&A strategy targets growth and margin expansion
M&A strategy targets growth and margin expansion TMVR & HF: High- mainly growth single- potential HF digit TMVR Neuromodulation: Growth Mid- margin and growth NM potential single- digit Cardiac Surgery: Low- mainly margin CS single- expansion digit Profitability improvement Illustrative only and not
Slide 11: Clear roadmap for value creation
Clear roadmap for value creation 2017-2018 2019-2020 2021+ Invest & Grow Accelerate Growth Positioned for Success • Global leader in VNS Therapy • Operational excellence • Global leader in cardiopulmonary • Global expansion of VNS • Global leader in sutureless valves Therapy leadership • Increasing
Slide 12: Four pillars to transform the organization
Four pillars to transform the organization GROWTH PROFITABILITY TALENT CULTURE 12
Slide 13: Strategy to accelerate growth
Strategy to accelerate growth Expand Drive demand Build pipeline portfolio 13
Slide 14: Significant opportunities to improve profitability
Significant opportunities to improve profitability Build better Spend better Price better Lean manufacturing SAP Direct implementation procurement Footprint Indirect consolidation Profitability procurement SKU Sales force rationalization effectiveness Pricing consistency 14
Slide 15: Integrated Talent Strategy
Attracting new talent and developing existing talent Attract Retain Develop Integrated Talent Strategy Total Talent Talent Talent Rewards Acquisition Analytics Development 15
Slide 16: Creating a culture of continuous improvement
Creating a culture of continuous improvement Discipline Accountability Teamwork Our size allows us We are blending We have a global Our mission is to to make decisions discipline and and diverse improve patients’ and implement accountability with workforce lives change swiftly an innovative spirit 1
Slide 17: We are a compelling investment
We are a compelling investment Leadership positions in most of our served markets Innovative products with patient/physician benefits Significant barriers to entry Opportunities for geographical expansion Multiple drivers to accelerate growth Executing on initiatives for margin expansion 17
Slide 18: We are poised for success
We are poised for success • Large, globally expanding markets • Broad geographic presence Top and Growing • Growing positions in head and heart bottom line • Customer-centric innovation • Realizing capital and operational efficiencies • Four pillars transforming organization Transforming Organizatio
Slide 19: LivaNova
LivaNova | ivaNova Health innovation that matters 19